Personal health and wellness is one of the many secular tailwinds for healthcare companies. Despite the rosy long-term ...

Regeneron Pharmaceuticals and Sanofi are conducting a Phase 3 clinical study titled A Randomized, Double-blind, Placebo-controlled, Parallel-group, 52-week Phase 3 Trial to Invest ...

The decision follows the initial approval granted in September 2023, which covered patients aged five years and above.

The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and ...

Patients with atopic dermatitis experienced improvements in severity with 16 weeks of tralokinumab despite the number of ...

This LSPN panel features experts from Maiwald, Regeneron, Vertex Pharmaceuticals, and Taylor Wessing discussing the impact of ...

The deal’s structure allows shareholders to benefit from potential future income streams, with payments linked to performance ...

When it comes to groundbreaking biotech advancements, Eric Faw Intellia is a name you might wanna keep an eye on. This ...

A promising experimental drug is one more sign of the impending disruption the booming Chinese biotech industry could bring ...

"If patients have one feature, that is bad, and if they have two or more, that is really bad," he said. "Regardless of ...

EPHA4 pathway dysfunction causes axon pathfinding defects, resulting in impaired coordinated left-right locomotion by disrupting neural patterning and the function of central pattern generators, ...

Wall Street trading got off to a mixed start on Tuesday as market participants digested key inflation data and Q2 bank ...